reports
- Daniel Appiah
Voyageur Pharmaceuticals advances barium product pipeline
Voyageur Pharmaceuticals has announced the successful formulation and engineering for production of HDXBa, another barium contrast product in the company's pipeline. Voyageur has a bold strategy to use its expertise in natural resources to create an integrated value chain in radiology contrast agen
- Daniel Appiah
Voyageur: Earthly profits from contrasting media
Voyageur Pharmaceuticals has a bold strategy to use its expertise in natural resources to create an integrated value chain in radiology contrast agents in North America (NA). The contrast business is big, over US$1.7bln in NA, dominated by a few large companies and constrained by raw material suppl
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.